AC5® Topical Gel Clinical (Human) Study
Randomized, blinded safety study of 46 patients undergoing cutaneous surgery, including 10 patients on antiplatelet therapy (blood thinner). Each patient underwent shave excision of 2 lesions, which were randomized to AC5® or control treatment.
AC5® met the primary safety and secondary performance endpoints
- Safety profiles similar between AC5®- and control-treated wounds (30-day follow up)
- No serious adverse effects noted
- 41% statistically significant improvement in median time to hemostasis (TTH) with AC5® vs control
- TTH ≤30 seconds in groups of AC5®-treated wounds (+/- antiplatelet therapy)
Rahmani G et al. Dermatol Surg. 2018;44:939–948.